Table 1. Optimal results for the drug discovery problems with different deficient conditions.

	Therapeutic effect				Therapeutic and adverse effects				Therapeutic, adverse and variation effects
Disease	T*	A	V	Detected target	T*	A*	V	Detected target	T*	A*	V*	Detected target
VM50	1	1	0.636	α13	1	1	0.636	α13	0.839	0.839	0.926	α15
VM70	1	1	0.107	α13	1	1	0.107	α13	0.818	0.873	0.818	α15, α60
VM90	1	0.651	0.009	α13, α15	0.994	0.994	0	α2, α13, α15	0.697	0.749	0.697	α13, α15, α60
VM95	1	0.052	0.019	α10, α13, α15	1	1	0.13	α6, α13, α15, α31	0.574	0.611	0.574	α13, α15, α16, α60
TH50	1	0.975	0.958	α56	1	1	0.543	α31	0.999	0.974	0.974	α42
TH70	1	0.945	0.826	α56	1	1	0.426	α9	0.97	0.92	0.92	α56
TH90	1	1	0.329	α2, α14	1	1	0.334	α2, α14	0.851	0.998	0.851	α14, ut
TH100	1	0.929	0.087	ut, ul	0.951	0.951	0.105	ut, ul	0.651	0.588	0.588	α2, α8, ut, ul, ud

VM50 and VM95 reflect 50% and 95% deficiency of VMAT2, respectively, whereas TH50 and TH100 indicate 50% and 100% deficiency of TH, respectively. Furthermore, u_t, u_l, and u_d denote the external control for tyrosine, L-DOPA, and intracellular dopamine, respectively. α_j is the enzyme activity for the j^th reaction rate. T, A, and V denote the satisfaction grade for therapeutic, adverse, and variation effects, respectively.

* indicates the optimal solution.